Verici Dx Achieves Key Collaboration Milestone

Verici Dx Plc (GB:VRCI) has released an update.

Verici Dx Plc, a developer of diagnostic tests for organ transplants, has successfully completed the technology transfer for pre-transplant prognostic testing to Thermo Fisher Scientific, as per their 2023 licensing and commercialization agreement. This achievement allows Thermo Fisher Scientific to develop a Laboratory Developed Test in their own labs and triggers an additional milestone payment for Verici Dx. The CEO of Verici Dx expressed satisfaction with the collaboration, anticipating benefits for patients and advancements in the field of organ transplantation.

For further insights into GB:VRCI stock, check out TipRanks’ Stock Analysis page.